Roche in 500 million-euro deal with reMYND to develop Parkinson's and Alzheimer's disease drugs

8 September 2010

Swiss drug major Roche (SIX: RO, ROG) has entered into an agreement with privately-held reMYND to develop novel therapeutics that could slow down neurodegeneration in Parkinson's and Alzheimer's patients by inhibiting alpha-synuclein and tau toxicity.

Under the terms of the deal, reMYND, a spin-off company of Leuven University in Belgium, could receive over 500 million euros ($643 million) in milestone payments, additional FTE payments and royalties on resulting net sales, potentially reaching a double-digit level.

Focus on two preclinical programs

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical